Dachaigh › Liomfoma Neo-Hodgkin › Nebraska
Sgrùdaidhean clionaigeach Liomfoma Neo-Hodgkin ann an Nebraska
Tha 15 sgrùdaidhean airson Liomfoma Neo-Hodgkin a’ lorg phàirtichean aig làraichean ann an Nebraska.
Bailtean ann an Nebraska
Teacsa sgrùdaidh oifigeil (Beurla)
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Nebraska Medical Center, Omaha
A’ fastadhÌre 2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT02693535A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- The University of Nebraska Medical Center, Omaha
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT07195916A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- Local Institution - 0124, Omaha
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT06090539Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Nebraska Cancer Specialists, Omaha
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT06806033Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Nebraska Medical Center, Omaha
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT05826535A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- University of Nebraska Medical Center, Omaha
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT06528301A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Nebraska Medical Center (UNMC), Omaha
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Lùna 2026 · NCT07188558A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Nebraska Medical Center, Omaha
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 6 Iuch 2026 · NCT01351545Halt Aging in Survivors of Blood Cancers
- University of Nebraska Medical Center, Omaha
A’ fastadh
Aoisean 50 agus nas sine · Gach gnè · Air ùrachadh 1 Iuch 2026 · NCT07292272Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Ògmh 2026 · NCT04068597CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Fred and Pamela Buffett Cancer Center, Omaha
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Gibl 2026 · NCT03328078Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- CHI Health Good Samaritan, Kearney
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Màrt 2026 · NCT06418204A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- University Of Nebraska Medical Center, Omaha
A’ fastadhÌre 4
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Màrt 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- University Of Nebraska Medical Center, Omaha
A’ fastadhÌre 4
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Màrt 2026 · NCT06876649SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 28 Dàmh 2025 · NCT03452774Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.